Global Insulin Biologics and Biosimilars Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Insulin Biologics and Biosimilars Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Insulin is a hormone created by your pancreas that controls the amount of glucose in your bloodstream at any given moment. It also helps store glucose in your liver, fat, and muscles. Finally, it regulates your body’s metabolism of carbohydrates, fats, and proteins.
Insulin Biologics and Biosimilars report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Insulin Biologics and Biosimilars market is projected to reach US$ 36510 million in 2029, increasing from US$ 25780 million in 2022, with the CAGR of 5.1% during the period of 2024 to 2029. Demand from Hospital and Retail Pharmacy are the major drivers for the industry.
The insulin biologics and biosimilars market is driven by the increasing prevalence of diabetes and the rising demand for effective and affordable insulin therapies. Insulin biologics play a critical role in managing diabetes and are widely used by patients worldwide. The growing diabetic population, along with the need for personalized and long-term insulin treatments, contributes to market growth. Additionally, advancements in biotechnology and insulin delivery systems have improved patient convenience and adherence. Biosimilars, which are highly similar versions of approved insulin biologics, offer cost-effective alternatives and have gained traction due to their potential to reduce healthcare expenditures and increase patient access. However, the market also faces challenges, including the complex regulatory pathway for biosimilars' approval, the need for extensive clinical comparability studies, and concerns regarding interchangeability and immunogenicity. Additionally, patent protection and market exclusivity of originator insulin products pose obstacles for biosimilar manufacturers. To succeed in this market, companies must navigate the regulatory landscape effectively, invest in research and development, demonstrate safety and efficacy of biosimilars, and collaborate with healthcare providers to promote the adoption of biosimilars and improve patient access to insulin therapies.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Insulin Biologics and Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Novo Nordisk
Eli Lilly
Sanofi
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt
Segment by Type
Insulin Biologics
Insulin Biosimilars
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Insulin Biologics and Biosimilars market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Insulin Biologics and Biosimilars introduction, etc. Insulin Biologics and Biosimilars Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Insulin Biologics and Biosimilars market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Insulin Biologics and Biosimilars report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Insulin Biologics and Biosimilars market is projected to reach US$ 36510 million in 2029, increasing from US$ 25780 million in 2022, with the CAGR of 5.1% during the period of 2024 to 2029. Demand from Hospital and Retail Pharmacy are the major drivers for the industry.
The insulin biologics and biosimilars market is driven by the increasing prevalence of diabetes and the rising demand for effective and affordable insulin therapies. Insulin biologics play a critical role in managing diabetes and are widely used by patients worldwide. The growing diabetic population, along with the need for personalized and long-term insulin treatments, contributes to market growth. Additionally, advancements in biotechnology and insulin delivery systems have improved patient convenience and adherence. Biosimilars, which are highly similar versions of approved insulin biologics, offer cost-effective alternatives and have gained traction due to their potential to reduce healthcare expenditures and increase patient access. However, the market also faces challenges, including the complex regulatory pathway for biosimilars' approval, the need for extensive clinical comparability studies, and concerns regarding interchangeability and immunogenicity. Additionally, patent protection and market exclusivity of originator insulin products pose obstacles for biosimilar manufacturers. To succeed in this market, companies must navigate the regulatory landscape effectively, invest in research and development, demonstrate safety and efficacy of biosimilars, and collaborate with healthcare providers to promote the adoption of biosimilars and improve patient access to insulin therapies.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Insulin Biologics and Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Novo Nordisk
Eli Lilly
Sanofi
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt
Segment by Type
Insulin Biologics
Insulin Biosimilars
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Insulin Biologics and Biosimilars market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Insulin Biologics and Biosimilars introduction, etc. Insulin Biologics and Biosimilars Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Insulin Biologics and Biosimilars market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices